The US government is tackling the costliest problem in the US: medical expenses. It started with the passing of last year’s Inflation Reduction Act, which gave Medicare — the US health insurance program for 57M seniors — the power to negotiate prices over certain drugs. Yesterday, Biden released the first ten drugs eligible for negotiations…
Read more
Eli Lilly Could Be Seeing Two Blockbuster Drug Launches in 2023
What’s better than one blockbuster drug? Two blockbuster drugs. That potential scenario has investors juiced up over Eli Lilly. Yesterday, the pharma giant released strong final-stage trial results for its Alzheimer’s drug Donanemab. Over 6M Americans are living with Alzheimer’s — expected to rise to 13M by 2050. It’s the most common cause of dementia,…
Read more
Why Are Drugmakers Lowering Insulin Prices?
The high cost of insulin has been a major issue for over 7M Americans: Insulin prices have risen over 600% in the past 20 years. 14% of US insulin users spent at least 40% of their income on the drug. Three companies dominate 90% of the insulin market: Eli Lilly, Novo Nordisk and Sanofi. In…
Read more
Pharma’s $200B “Patent Cliff” Problem Is Biotech’s Opportunity
Something big is brewing in the pharma-biotech industry. We’ve seen it before, and it’s led to some impressive sector returns. Scared of heights? This one’s a 456ft Kingda Ka that’s got the pharma execs on high alert. The pharma industry is reaching a major patent cliff. What is it, and why is this a major…
Read more
Are weight-loss treatments the blockbuster drugs of the decade?
This drug may finally put an end to all those fitness fads that make you question why they were ever created. (Shake Weight 👀). Introducing — GLP-1-based drugs that treat diabetes and obesity. Several have been approved in the past two years — stimulating hormones that make you feel full. The rich are using them…
Read more
Illumina unveils new DNA sequencing machines; can it out-innovate its competition?
“Baymax, sequence my DNA and diagnose my disease…” Twenty years ago, that would have cost you over $100 million. Thanks to technological advancements, it’ll soon cost $200. Gene/DNA sequencing is the process of analyzing your DNA — which can help speed up drug development and research and help diagnose rare diseases (i.e., cancer). More than…
Read more
The FDA is considering over-the-counter birth control pills
Birth control pills were approved over 60 years ago. In November, the FDA will be considering an application to sell over-the-counter birth control at pharmacies for the first time. The two candidates being considered are made by: HRA Pharma — a subsidiary of pharmaceutical manufacturer Perrigo Company (NYSE:PRGO). Cadence Health — a startup focused on…
Read more
The obesity market is expected to grow into a $54B market — dominated by these two companies
And it doesn’t involve eating less or exercising. All it requires is $1,000-$1,500 a month and potential nausea or diarrhea. After years of failed drugs, a new class of weight loss drugs reached the market last year — proving to be highly effective. Weighing the 1.2 million tonne problem Obesity can lead to heart disease…
Read more
Psychedelic stocks in focus with test trial results coming
The use of psychedelics for depression treatment has made substantial progress in recent years. And industry scientists and entrepreneurs in the industry are expecting FDA approval for its use in medical treatment as early as 2024. Watch for: An important date is coming in the psychedelics industry. A Compass-sponsored trial is testing 3 different doses…
Read moreETF Spotlight: The first US Psychedelics ETF begins trading
ETF: Defiance Next Gen Altered Experience ETF (NYSE:PSY) Launched last week, $PSY is an ETF that holds 20 companies in the production, distribution, or services related to psychedelics, medical cannabis, and ketamine for health treatments. ETF launch date: May 28, 2021 Top 3 Holdings: Charlottes Web Holdings Inc (TSE:CWEB), Aurora Cannabis (NASDAQ:ACB), Cronos Group (TSE:CRON)…
Read more